What this pack is
Coumadin is the brand name in this record; warfarin is the generic name. Read both together with the dosage form (multiple forms (oral tablets and injectable product)).
PACK CHECK · MARKET FIRST
CoumadinGeneric namewarfarin
How this medicine works
The FDA public label explains that warfarin affects synthesis of vitamin K-dependent clotting factors II, VII, IX and X, as well as anticoagulant proteins C and S; it describes interference with the VKORC1 enzyme complex. This helps explain why monitoring, the medicine list and dietary changes need to be discussed together, but it does not derive an individual's dose, INR target, diet adjustment or conversion plan.
Read source: United States ↗Historical public record · reviewed 2026-08-20More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- International brand name
- Coumadin
- Generic name
- warfarin
- Dosage-form class
- Dosage form and presentation as documented in the linked primary label
- Route
- Oral / intravenous injection
- Package-image status
- No exact original-brand package image is shown This is deliberate: do not use a retailer, repackager or another-market image to identify the pack in hand. See why and what to check instead →
No source-verifiable mainland-China trade-name cue has been established for this record. This does not establish whether the medicine exists, is approved or is available in mainland China. Check pack text and current CDE/NMPA records item by item.
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
A vial concentration, unit-per-mL value or device marking identifies the exact labelled product. It does not calculate an individual's amount, timing, administration, missed-use action, combination or switch.
These nine historical COUMADIN tablet identities are all single-scored. A score line identifies the reviewed historical tablet appearance; it does not permit self-splitting, changing the amount, INR adjustment, make-up use or switching. The historical injection is a separately sourced text-only identity card and never creates an oral-to-injection conversion, reconstitution or administration instruction.
How to read a score line: ‘scored’ or ‘unscored’ first identifies this labelled presentation. A score line by itself does not permit self-splitting, reducing or changing the product. Only an explicit statement in the current label for this exact presentation, checked with a pharmacist against the prescription, can support any further handling.
10 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · FDA U.S. historical label (revised Oct 2015; may not be the latest approved label)
Warfarin sodium 1 mg per tablet; 100-tablet bottle (historical label text)
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- NDC 0056-0169-70
- Form and route
- warfarin sodium single-scored oral tablet (historical label) · oral
- Container
- bottle
- warfarin sodium
- 1 mghistorical labelled amount per tablet; not an individual tablet count, INR adjustment, make-up-use or conversion instruction
- Package
- 100 tablets per bottle
- Labelled appearance
- pink · single-scored tablet · imprint COUMADIN / 1 (one face); plain opposite faceScored appearance; this is not a self-splitting instruction
United States label · FDA U.S. historical label (revised Oct 2015; may not be the latest approved label)
Warfarin sodium 2 mg per tablet; 100-tablet bottle (historical label text)
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- NDC 0056-0170-70
- Form and route
- warfarin sodium single-scored oral tablet (historical label) · oral
- Container
- bottle
- warfarin sodium
- 2 mghistorical labelled amount per tablet; not an individual tablet count, INR adjustment, make-up-use or conversion instruction
- Package
- 100 tablets per bottle
- Labelled appearance
- lavender · single-scored tablet · imprint COUMADIN / 2 (one face); plain opposite faceScored appearance; this is not a self-splitting instruction
United States label · FDA U.S. historical label (revised Oct 2015; may not be the latest approved label)
Warfarin sodium 2.5 mg per tablet; 100-tablet bottle (historical label text)
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- NDC 0056-0176-70
- Form and route
- warfarin sodium single-scored oral tablet (historical label) · oral
- Container
- bottle
- warfarin sodium
- 2.5 mghistorical labelled amount per tablet; not an individual tablet count, INR adjustment, make-up-use or conversion instruction
- Package
- 100 tablets per bottle
- Labelled appearance
- green · single-scored tablet · imprint COUMADIN / 2-1/2 (one face); plain opposite faceScored appearance; this is not a self-splitting instruction
United States label · FDA U.S. historical label (revised Oct 2015; may not be the latest approved label)
Warfarin sodium 3 mg per tablet; 100-tablet bottle (historical label text)
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- NDC 0056-0188-70
- Form and route
- warfarin sodium single-scored oral tablet (historical label) · oral
- Container
- bottle
- warfarin sodium
- 3 mghistorical labelled amount per tablet; not an individual tablet count, INR adjustment, make-up-use or conversion instruction
- Package
- 100 tablets per bottle
- Labelled appearance
- tan · single-scored tablet · imprint COUMADIN / 3 (one face); plain opposite faceScored appearance; this is not a self-splitting instruction
United States label · FDA U.S. historical label (revised Oct 2015; may not be the latest approved label)
Warfarin sodium 4 mg per tablet; 100-tablet bottle (historical label text)
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- NDC 0056-0168-70
- Form and route
- warfarin sodium single-scored oral tablet (historical label) · oral
- Container
- bottle
- warfarin sodium
- 4 mghistorical labelled amount per tablet; not an individual tablet count, INR adjustment, make-up-use or conversion instruction
- Package
- 100 tablets per bottle
- Labelled appearance
- blue · single-scored tablet · imprint COUMADIN / 4 (one face); plain opposite faceScored appearance; this is not a self-splitting instruction
United States label · FDA U.S. historical label (revised Oct 2015; may not be the latest approved label)
Warfarin sodium 5 mg per tablet; 100-tablet bottle (historical label text)
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- NDC 0056-0172-70
- Form and route
- warfarin sodium single-scored oral tablet (historical label) · oral
- Container
- bottle
- warfarin sodium
- 5 mghistorical labelled amount per tablet; not an individual tablet count, INR adjustment, make-up-use or conversion instruction
- Package
- 100 tablets per bottle
- Labelled appearance
- peach · single-scored tablet · imprint COUMADIN / 5 (one face); plain opposite faceScored appearance; this is not a self-splitting instruction
United States label · FDA U.S. historical label (revised Oct 2015; may not be the latest approved label)
Warfarin sodium 6 mg per tablet; 100-tablet bottle (historical label text)
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- NDC 0056-0189-70
- Form and route
- warfarin sodium single-scored oral tablet (historical label) · oral
- Container
- bottle
- warfarin sodium
- 6 mghistorical labelled amount per tablet; not an individual tablet count, INR adjustment, make-up-use or conversion instruction
- Package
- 100 tablets per bottle
- Labelled appearance
- teal · single-scored tablet · imprint COUMADIN / 6 (one face); plain opposite faceScored appearance; this is not a self-splitting instruction
United States label · FDA U.S. historical label (revised Oct 2015; may not be the latest approved label)
Warfarin sodium 7.5 mg per tablet; 100-tablet bottle (historical label text)
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- NDC 0056-0173-70
- Form and route
- warfarin sodium single-scored oral tablet (historical label) · oral
- Container
- bottle
- warfarin sodium
- 7.5 mghistorical labelled amount per tablet; not an individual tablet count, INR adjustment, make-up-use or conversion instruction
- Package
- 100 tablets per bottle
- Labelled appearance
- yellow · single-scored tablet · imprint COUMADIN / 7-1/2 (one face); plain opposite faceScored appearance; this is not a self-splitting instruction
United States label · FDA U.S. historical label (revised Oct 2015; may not be the latest approved label)
Warfarin sodium 10 mg per tablet; 100-tablet bottle (historical label text)
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- NDC 0056-0174-70
- Form and route
- warfarin sodium single-scored oral tablet (historical label) · oral
- Container
- bottle
- warfarin sodium
- 10 mghistorical labelled amount per tablet; not an individual tablet count, INR adjustment, make-up-use or conversion instruction
- Package
- 100 tablets per bottle
- Labelled appearance
- white (dye-free) · single-scored tablet · imprint COUMADIN / 10 (one face); plain opposite faceScored appearance; this is not a self-splitting instruction
United States label · FDA U.S. historical label (revised Oct 2015; may not be the latest approved label)
Warfarin sodium 5 mg per vial; carton of 6 vials (historical label text)
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- NDC 0590-0324-35
- Form and route
- warfarin sodium lyophilized powder for intravenous injection (historical label) · intravenous injection (label identity only)
- Container
- vial carton
- warfarin sodium
- 5 mghistorical labelled amount per vial; not an individual injection amount, reconstitution, administration-rate, adjustment or conversion instruction
- Package
- 6 vials per carton
PACKAGE-VISUAL STATUS
A repackaged historical label was located, so it is not shown as an original-brand package
The searchable historical DailyMed COUMADIN record is identified as repackaged. It can trace the trade name, warfarin sodium, 1 mg, 90 tablets and historical NDC 54868-2128-3, but cannot be presented as this record's exact original-brand package image. To avoid treating a repackaged label as original-brand appearance, this dossier withholds the image and retains the public label as a text-verification entry.
LABEL READING · NOT A PRESCRIPTION
COUMADIN label reading: mg, INR and the full medicine list belong together
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
This module explains product-identity and risk-reading clues in the 2015 U.S. FDA label archive only. It does not calculate warfarin dosage, INR targets, missed-dose handling, diet changes or conversion plans.
- This U.S. label lists scored tablet strengths including 1, 2, 2.5, 3, 4, 5, 6, 7.5 and 10 mg, as well as an injectable presentation. mg identifies a specific product unit; it is not an answer to a person's daily tablet count and cannot be self-adjusted from colour, score marks or a number alone.
- The label identifies INR monitoring as important and notes that medicines, dietary changes and other factors can affect INR. Any new prescription, OTC product, herb/supplement, antibiotic or major diet change should be reviewed through the responsible team's established process, not self-adjusted from a webpage or someone else's experience.
- The label says genotype information can inform initial dose selection, but that does not mean everyone should independently obtain broad genetic screening or use a report to start, stop or change an anticoagulant. If a result already exists, a professional should interpret it with the full history, monitoring record and medicine list.
- Unexpected bleeding, black stools, vomiting blood, a fall or head injury, or a planned surgical/dental procedure are not situations to manage from a webpage alone; contact the responsible local team or emergency medical services promptly.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkFDA · United States · Regulatory product record or label archive · 2026-08-20
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 1
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeFDA: COUMADIN 2015 U.S. label (NDA 009218) ↗Historical public record · reviewed 2026-08-20
Reviewed official safety records
A dated record is not automatically a current alert. Read the named product, form, batch, market, date and source type before treating it as relevant.
- FDA pharmacogenomic label record: warfarin and CYP2C9 / VKORC12025-12 · FDA’s Table of Pharmacogenomic Biomarkers in Drug Labeling lists warfarin (Coumadin) with CYP2C9 / VKORC1-related labeling information. The table is a U.S. regulator index to where genomic information appears in labeling; it does not mean every user needs screening, that a tested person should self-change a dose, or that another medicine may be substituted independently. Whether to test, how to interpret a result and how it relates to other medicines must be reviewed with the exact product, indication, current label and complete medicine list by the prescribing team or pharmacist.Primary-source record (open linked document) ↗reviewed 2026-08-22
Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about Coumadin (warfarin). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
Coumadin is the brand in this record and warfarin is the active-ingredient name. Check both with the dosage form (Dosage form and presentation as documented in the linked primary label) and the market on the actual pack.
Read the labelled strength in context
mg/mL, mg per vial or a total volume describes the labelled concentration or pack identity of an injectable product. It is not an individual infusion amount, preparation instruction or schedule.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a severe reaction, fainting, difficulty breathing or sudden worsening symptoms around an injection or infusion, use the local treatment team or emergency service now. Do not wait for a website reply or alter preparation, infusion or another medicine yourself.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
CO-MEDICATION REVIEW · NOT A TREATMENT DECISION
When TYLENOL Extra Strength is on the same list: an analgesic or fever medicine also needs review first
The U.S. public Drug Facts for TYLENOL Extra Strength says to ask a doctor or pharmacist before use when taking warfarin. This card only signals that the actual TYLENOL pack, warfarin pack, other pain/cold products, prescription medicines, OTC products and supplements need review by the responsible team; it does not decide co-use or advise self-stopping, time-separation, replacement or adjustment of either medicine.
Open the Tylenol Extra Strength / acetaminophen record →
Add both records to this device's family medicine list →
Open the primary source for this co-medication review cue ↗reviewed 2026-08-20CO-MEDICATION REVIEW · NOT A TREATMENT DECISION
When ADVIL / ibuprofen is on the same list: an anticoagulant calls for a complete medicine-list review first
The current U.S. public Drug Facts for ADVIL lists use of a blood-thinning anticoagulant as a risk cue in its stomach-bleeding warning. This card only signals that the actual Advil pack, warfarin pack, other pain/cold products, prescription medicines, OTC products and supplements need review by the responsible team; it does not decide co-use or advise self-stopping, time-separation, replacement or adjustment of either medicine.
Open the Advil / ibuprofen record →
Add both records to this device's family medicine list →
Open the primary source for this co-medication review cue ↗reviewed 2026-08-20CO-MEDICATION REVIEW · NOT A TREATMENT DECISION
When TRULICITY / dulaglutide is on the same list: review a narrow-therapeutic-index oral medicine first
The FDA's 2025 TRULICITY label says it delays gastric emptying and may reduce the rate of absorption of concomitant oral medicines; it names warfarin as an example of an oral medicine with a narrow therapeutic index for which professionals monitor drug levels. This card only signals that warfarin, TRULICITY, every actual pack, OTC product and supplement should be reviewed by a pharmacist or prescriber; it provides no individual monitoring target, timing interval or adjustment plan and does not decide co-use or advise self-stopping, time-separation, replacement or adjustment of either medicine.
Open the Trulicity / dulaglutide record →
Add both records to this device's family medicine list →
Open the primary source for this co-medication review cue ↗reviewed 2026-08-20CO-MEDICATION REVIEW · NOT A TREATMENT DECISION
When BAYER LOW DOSE ASPIRIN / aspirin 81 mg is on the same list: review the complete medicine list first
The current U.S. public Drug Facts for BAYER LOW DOSE ASPIRIN lists use of an anticoagulant as a cue that needs review in its stomach-bleeding warning. This card only signals that the actual aspirin pack, warfarin pack, other pain/cold products, prescriptions, OTC products, herbs and supplements need review by a pharmacist or clinician; it does not decide whether anyone can use them together or advise self-stopping, time-separation, replacement or adjustment of either medicine. Starting a medicine or making another change also needs pharmacist or clinician review.
Open the BAYER LOW DOSE ASPIRIN / aspirin record →
Add both records to this device's family medicine list →
Open the primary source for this co-medication review cue ↗reviewed 2026-08-20CO-MEDICATION REVIEW · NOT A TREATMENT DECISION
When CORDARONE / amiodarone is on the same list: this is a high-risk professional-monitoring check
A current U.S. generic warfarin label lists amiodarone among medicines requiring interaction review, while a current generic amiodarone label also notes that interactions can persist for weeks to months after amiodarone is stopped. This card only signals that both actual packs, current labels, monitoring records and the complete medicine list need prompt review by the prescribing team, pharmacist or anticoagulation service; it does not decide co-use, provide an INR target, dose, timing interval or stop/switch plan, or advise self-stopping, time-separation, replacement or adjustment of either medicine. The COUMADIN and CORDARONE pages include historical brand archives; current generic labels do not establish current brand supply or market status.
Open the CORDARONE / amiodarone hydrochloride record →
Add both records to this device's family medicine list →
Open the primary source for this co-medication review cue ↗Current regulatory record · reviewed 2026-09-05CO-MEDICATION REVIEW · NOT A TREATMENT DECISION
When CRAVIT / LEVAQUIN is on the same list: review INR and bleeding-monitoring records first
The FDA's 2019 historical U.S. oral-tablet label for LEVAQUIN lists warfarin as a medicine requiring review and describes postmarketing reports of enhanced warfarin effect, increased prothrombin time or INR, and bleeding episodes. The document also states that it may not be FDA's latest approved label. This card is therefore only a dated, U.S., ingredient-level priority-review cue: promptly take both actual packs, current target-market labels, recent monitoring records, and every prescription, OTC product and supplement to the prescribing team, pharmacist or anticoagulation service. It does not decide individual co-use, provide an INR target, tablet count, timing interval or stop/switch plan, or advise self-stopping, time-separation, replacement or adjustment of either medicine.
Open the Levaquin / levofloxacin record →
Add both records to this device's family medicine list →
Open the primary source for this co-medication review cue ↗Historical public record · reviewed 2026-09-13HOW IT WORKS · NOT A TREATMENT PLAN
How warfarin works: it affects synthesis of vitamin K-dependent clotting factors
- This mechanism does not mean that eating less or more of one food can be used for self-correction. Any meaningful dietary change, antibiotic, herb/supplement, OTC product or new prescription needs review through the responsible team's established INR-monitoring process.
- “Affecting the vitamin K pathway” is not a reason for broad genetic screening or self-adjustment from a genetic report. Genomic information in the label should be interpreted by a professional together with history, monitoring results and the complete medicine list.
- Mechanism cannot decide whether to use another anticoagulant or antiplatelet medicine together, how to handle missed use or when to interrupt treatment. For unexpected bleeding, black stools, vomiting blood, a fall or head injury, contact the responsible local team or emergency medical services.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- FDA: COUMADIN 2015 U.S. label (NDA 009218) ↗Historical public record · reviewed 2026-08-20
- FDA Drugs@FDA official search entry ↗Official lookup entry · reviewed 2026-08-20
SOURCE-TRACEABLE ARCHIVE
Coumadinwarfarin
This page links to public primary-source material for Coumadin. The archive is historical or documentary evidence only; it does not by itself establish originator status, product quality, current labelling, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
Initial U.S. approval year listed in the FDA label
The FDA label archive linked here lists Initial U.S. Approval: 1954. This historical locator is not a conclusion about current approval, availability, holder or another market.
FDA: COUMADIN label archive ↗FDA label archive version
This page links the 2015-10 FDA label archive as a traceable reading entry point. Current labeling, strength, indication and safety information require separate verification against the target market’s current document.
FDA: COUMADIN label archive ↗
MARKET SCOPE
Market-record boundary
United States
Public label archive linkedOnly the FDA document listed on this page is linked.
Mainland China, EU, Japan
Market record not establishedNo local approval, holder, strength, supply or sale-eligibility conclusion is inferred from the U.S. label archive.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
Keep international and mainland China records separate
This page has a U.S. public history/regulatory archive but no mainland China record for this specific product. That does not establish whether the medicine exists, is approved or is available in mainland China. Verify product identity, dosage form, strength, holder and the current label item by item.
RECORD FAQ
Record questions
Does a label archive represent current product information?
Not automatically. The archive locates a source; each point needs verification against the target market’s current official label.
Why are price and originator/generic conclusions not shown?
Those conclusions require separately complete and human-reviewed product, dosage-form, strength, pack, market, date and primary-record fields; one label file is insufficient.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.